All Stories

  1. Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder

    Article • ClinicoEconomics and Outcomes Research, December 2019, Taylor & Francis

    Mallik Greene, Ann Hartry

  2. Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data

    Article • Current Medical Research and Opinion, January 2019, Taylor & Francis

    Mallik Greene, Ann Hartry

  3. Evaluation of patient support program and adherence to long-acting injectable aripiprazole for patients utilizing injection local care centers

    Article • Current Medical Research and Opinion, November 2018, Taylor & Francis

    Mallik Greene

  4. Atypical antipsychotic adherence is associated with lower inpatient utilization and cost in bipolar I disorder

    Article • Journal of Medical Economics, October 2018, Taylor & Francis

    Mallik Greene, Ann Hartry

  5. A real-world analysis of healthcare costs and relative risk of hyperprolactinemia associated with antipsychotic treatments in the United States

    Article • Journal of Medical Economics, September 2018, Taylor & Francis

    Mallik Greene, Maelys Touya

  6. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder

    Article • Journal of Medical Economics, June 2018, Taylor & Francis

    Mallik Greene, Ann Hartry

  7. Systematic literature review on patterns of pharmacological treatment and adherence among patients with bipolar disorder type I in the USA

    Article • June 2018, Dove Medical Press

    Maelys Touya, Mallik Greene

  8. Budget impact analysis of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA

    Article • Journal of Comparative Effectiveness Research, April 2018, Future Medicine

    Mallik Greene

  9. Cost–effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA

    Article • Journal of Comparative Effectiveness Research, April 2018, Future Medicine

    Mallik Greene